92.95
2.95 (3.28%)
| Penutupan Terdahulu | 90.00 |
| Buka | 89.35 |
| Jumlah Dagangan | 4,790,516 |
| Purata Dagangan (3B) | 6,287,002 |
| Modal Pasaran | 55,364,755,456 |
| Harga / Jualan (P/S) | 20.97 |
| Harga / Buku (P/B) | 19.48 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 22 Aug 2025 |
| Margin Keuntungan | -71.82% |
| Margin Operasi (TTM) | -43.15% |
| EPS Cair (TTM) | -2.99 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 59.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 154.06% |
| Nisbah Semasa (MRQ) | 0.920 |
| Aliran Tunai Operasi (OCF TTM) | -876.33 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -510.07 M |
| Pulangan Atas Aset (ROA TTM) | -15.27% |
| Pulangan Atas Ekuiti (ROE TTM) | -56.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | REMEGEN | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.13 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| REMEGEN | 55 B | - | - | 19.48 |
| ASYMCHEM | 37 B | 1.17% | 25.48 | 1.44 |
| ZAI LAB | 17 B | - | - | 2.92 |
| HBM HOLDINGS-B | 11 B | - | 18.47 | 5.17 |
| AKESO | 111 B | - | - | 15.36 |
| PHARMARON | 56 B | 0.92% | 22.04 | 2.39 |
|
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 11.60% |
| % Dimiliki oleh Institusi | 29.12% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |